Unique ID issued by UMIN | UMIN000003085 |
---|---|
Receipt number | R000003747 |
Scientific Title | Effects of branched-chain amino acids support in patients undergoing radiofrequency ablation for hepatocellular carcinoma: a randomized controlled study |
Date of disclosure of the study information | 2010/02/01 |
Last modified on | 2013/08/20 09:34:19 |
Effects of branched-chain amino acids support in patients undergoing radiofrequency ablation for hepatocellular carcinoma: a randomized controlled study
Effects of branched-chain amino acids support in patients undergoing radiofrequency ablation for hepatocellular carcinoma: a randomized controlled study
Effects of branched-chain amino acids support in patients undergoing radiofrequency ablation for hepatocellular carcinoma: a randomized controlled study
Effects of branched-chain amino acids support in patients undergoing radiofrequency ablation for hepatocellular carcinoma: a randomized controlled study
Japan |
hepatocellular carcinoma
Hepato-biliary-pancreatic medicine |
Malignancy
NO
target population:patients with liver cirhosis and early-stagehepatocellular carcinoma
Aim:Evaluation of the benefit of oral branched chain amino acids in patients with hepatocellularcarcinoma undergoing local ablation treatment.
Efficacy
Confirmatory
Pragmatic
Phase III
Short- to mid-term effects of liver function and nutrition status during the post ablative period.
Time to tumor progression
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
The patients in the BCAA group received BCAA orally administration before tumor ablation therapy until 1 month after the therapy.
The patients in the diet group received diet therapy with defined daily food intake.
20 | years-old | <= |
Not applicable |
Male and Female
1)Early-stage hepatocellular carcinoma(BCLC staging)
2)Compensated liver cirrhosis
3) Equal to or more than 20 years old.
Exclusion criteria are the presence of any one of the following: serum albumin <2.5mg dL, serum total bilirubin level <3mg/dL, hepatic encephalopathy of or above grade II, history of albumin infusion or receiving BCAA granules in the preceding 3 months, and bleeding varices.
80
1st name | |
Middle name | |
Last name | Manabu Morimoto |
Yokohama City University Medical Center
Gastroenterological Center
4-57, Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan
045-261-5656
1st name | |
Middle name | |
Last name | Manabu Morimoto |
Yokohama City University Medical Center
Gastroenterological Center
4-57, Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan
045-261-5656
morimoto@urahp.yokohama-cu.ac.jp
Yokohama City University Medical Center Gastroenterological Center
None
Self funding
NO
横浜市立大学附属市民総合医療センター (神奈川県)
2010 | Year | 02 | Month | 01 | Day |
Unpublished
Terminated
2010 | Year | 01 | Month | 25 | Day |
2012 | Year | 01 | Month | 01 | Day |
2013 | Year | 01 | Month | 01 | Day |
2010 | Year | 01 | Month | 25 | Day |
2013 | Year | 08 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003747
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |